Visual Capitalist November 28, 2024
This graphic visualizes R&D spending growth (or decline) from 2022 to 2023 for major pharmaceutical companies. Data was sourced from the Global Innovation Index 2024, an annual report produced by the World Intellectual Property Office (WIPO).
A key takeaway from this dataset is that Eli Lilly, Novartis, and Merck all increased their R&D spending by over 20%.
Data and Highlights
The data featured in this infographic is also listed in the table below. Note that this is not an exhaustive list of companies, with one notable exclusion being Novo Nordisk, the maker of Ozempic.
| Country | Company | R&D Spending Change (%) |
|---|---|---|
| 🇺🇸 US | Eli Lilly | 29.5 |
| 🇨🇭 Switzerland | Novartis | 24.0 |
Today's Sponsors
Today's Sponsor